OA10697A - Injectable quinolone formulations. - Google Patents

Injectable quinolone formulations. Download PDF

Info

Publication number: OA10697A
Authority: OA; OAPI
Prior art keywords: solution; danofloxacin; added; formulation; pvp
Prior art date: 1995-12-21

Application number

OA9800082A

Other languages

English (en)

Inventor

Wayne Alan Boettner

Peter Connor Canning

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-21

Filing date

1998-06-12

Publication date

2001-05-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-12 Application filed by Pfizer filed Critical Pfizer

2001-05-04 Publication of OA10697A publication Critical patent/OA10697A/en

Links

239000000203 mixture Substances 0.000 title description 71
238000009472 formulation Methods 0.000 title description 66
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 claims abstract description 35
229960004385 danofloxacin Drugs 0.000 claims abstract description 35
239000007924 injection Substances 0.000 claims abstract description 24
238000002347 injection Methods 0.000 claims abstract description 24
239000006184 cosolvent Substances 0.000 claims abstract description 19
150000003752 zinc compounds Chemical class 0.000 claims abstract description 11
239000003186 pharmaceutical solution Substances 0.000 claims abstract description 9
239000000243 solution Substances 0.000 claims description 77
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 29
150000001875 compounds Chemical class 0.000 claims description 12
-1 magnésium compound Chemical class 0.000 claims description 12
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 8
208000035143 Bacterial infection Diseases 0.000 claims description 6
208000022362 bacterial infectious disease Diseases 0.000 claims description 6
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 5
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 4
239000003963 antioxidant agent Substances 0.000 claims description 3
230000003078 antioxidant effect Effects 0.000 claims description 3
238000000034 method Methods 0.000 claims description 3
238000010254 subcutaneous injection Methods 0.000 claims description 3
239000007929 subcutaneous injection Substances 0.000 claims description 3
239000004698 Polyethylene Substances 0.000 claims 1
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
229920000573 polyethylene Polymers 0.000 claims 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 21
150000003839 salts Chemical class 0.000 abstract description 3
229910052749 magnesium Inorganic materials 0.000 abstract 1
239000011777 magnesium Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
MYDXUJMODAZBGN-UHFFFAOYSA-N 6-bromo-5-methyl-2-methylsulfanyl-1h-[1,2,4]triazolo[1,5-a]pyrimidin-7-one Chemical compound CC1=C(Br)C(=O)N2NC(SC)=NC2=N1 MYDXUJMODAZBGN-UHFFFAOYSA-N 0.000 description 38
229960004745 danofloxacin mesylate Drugs 0.000 description 38
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 29
229910000041 hydrogen chloride Inorganic materials 0.000 description 29
238000013019 agitation Methods 0.000 description 17
VYGBQXDNOUHIBZ-UHFFFAOYSA-L sodium formaldehyde sulphoxylate Chemical compound [Na+].[Na+].O=C.[O-]S[O-] VYGBQXDNOUHIBZ-UHFFFAOYSA-L 0.000 description 15
239000002002 slurry Substances 0.000 description 13
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
239000000463 material Substances 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
239000000725 suspension Substances 0.000 description 6
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 5
239000004246 zinc acetate Substances 0.000 description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
HRKQOINLCJTGBK-UHFFFAOYSA-L dioxidosulfate(2-) Chemical compound [O-]S[O-] HRKQOINLCJTGBK-UHFFFAOYSA-L 0.000 description 4
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
239000010931 gold Substances 0.000 description 4
229910052737 gold Inorganic materials 0.000 description 4
229910052725 zinc Inorganic materials 0.000 description 4
239000011701 zinc Substances 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
235000019282 butylated hydroxyanisole Nutrition 0.000 description 3
244000309466 calf Species 0.000 description 3
ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 3
235000014655 lactic acid Nutrition 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
239000011787 zinc oxide Substances 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
239000004255 Butylated hydroxyanisole Substances 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
229940043253 butylated hydroxyanisole Drugs 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
229960004106 citric acid Drugs 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
229940001584 sodium metabisulfite Drugs 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028320 muscle necrosis Diseases 0.000 description 1
LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Inorganic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Communicable Diseases (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

OA9800082A 1995-12-21 1998-06-12 Injectable quinolone formulations. OA10697A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US905295P	1995-12-21	1995-12-21

Publications (1)

Publication Number	Publication Date
OA10697A true OA10697A (en)	2001-05-04

Family

ID=21735307

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800082A OA10697A (en)	1995-12-21	1998-06-12	Injectable quinolone formulations.

Country Status (42)

Country	Link
US (1)	US5811130A (fr)
EP (1)	EP0868183B1 (fr)
JP (1)	JP3416145B2 (fr)
KR (1)	KR100402570B1 (fr)
CN (1)	CN1104899C (fr)
AP (1)	AP706A (fr)
AR (1)	AR005147A1 (fr)
AT (1)	ATE212551T1 (fr)
AU (1)	AU709474B2 (fr)
BG (1)	BG63933B1 (fr)
BR (1)	BR9612230A (fr)
CA (1)	CA2239352C (fr)
CO (1)	CO4480098A1 (fr)
CZ (1)	CZ293747B6 (fr)
DE (1)	DE69618987T2 (fr)
DK (1)	DK0868183T3 (fr)
DZ (1)	DZ2146A1 (fr)
EG (1)	EG24071A (fr)
ES (1)	ES2167609T3 (fr)
GT (1)	GT199600098A (fr)
HR (1)	HRP960607B1 (fr)
HU (1)	HU227918B1 (fr)
IL (1)	IL124454A (fr)
IS (1)	IS2010B (fr)
MA (1)	MA24035A1 (fr)
MX (1)	MX9805026A (fr)
MY (1)	MY117109A (fr)
NO (1)	NO315734B1 (fr)
NZ (2)	NZ501160A (fr)
OA (1)	OA10697A (fr)
PE (1)	PE25798A1 (fr)
PL (1)	PL186795B1 (fr)
PT (1)	PT868183E (fr)
RS (1)	RS49523B (fr)
RU (1)	RU2141827C1 (fr)
SI (1)	SI0868183T1 (fr)
SK (1)	SK284412B6 (fr)
TN (1)	TNSN96163A1 (fr)
TW (1)	TW449475B (fr)
UA (1)	UA56151C2 (fr)
WO (1)	WO1997023217A1 (fr)
ZA (1)	ZA9610780B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ID21415A (id) *	1997-12-05	1999-06-10	Upjohn Co	Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) *	1998-10-30	2000-01-25	Supergen, Inc.	Water-miscible pharmaceutical compositions
DE19937116A1 (de) *	1999-08-06	2001-02-08	Bayer Ag	Moxifloxacin Kochsalzformulierung
DE19937115A1 (de)	1999-08-06	2001-02-08	Bayer Ag	Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
AU2001228454A1 (en) *	2000-01-13	2001-07-24	Merck Patent G.M.B.H	Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
WO2002053136A1 (fr)	2000-12-28	2002-07-11	Takeda Chemical Industries, Ltd.	Preparations a liberation soutenue
EP1524997A1 (fr) *	2002-06-26	2005-04-27	Pharmacia Corporation	Formulation de parecoxib liquide stable administree par voie parenterale
EP1764102A4 (fr) *	2004-07-02	2010-08-25	Daiichi Seiyaku Co	Composition médicinale contenant de la quinolone
MX359219B (es) *	2005-05-18	2018-09-19	Raptor Pharmaceuticals Inc	Fluoroquinolonas aerosolizadas y sus usos.
US8524735B2 (en)	2005-05-18	2013-09-03	Mpex Pharmaceuticals, Inc.	Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr)	2006-01-24	2010-08-13	Vetoquinol	Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
RU2008136460A (ru) *	2006-02-10	2010-03-20	Пари Фарма ГмбХ (DE)	Фармацевтический аэрозоль
US20070197548A1 (en)	2006-02-17	2007-08-23	Murthy Yerramilli V S	Fluoroquinolone compositions
DE102006010642A1 (de) *	2006-03-08	2007-09-27	Bayer Healthcare Aktiengesellschaft	Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) *	2006-03-08	2007-09-13	Bayer Healthcare Aktiengesellschaft	Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es)	2007-08-14	2009-02-25	Cell Therapy And Technology S	Gel conteniendo pirfenidona.
CA2739897C (fr)	2008-10-07	2017-10-03	Mpex Pharmaceuticals, Inc.	Formulations a base de fluoroquinolone sous forme d'aerosol pour une pharmacocinetique amelioree
CA2739893C (fr)	2008-10-07	2016-10-04	Mpex Pharmaceuticals, Inc.	Inhalation de levofloxacine pour reduire une inflammation des poumons
SI2473170T1 (sl)	2009-09-04	2019-10-30	Horizon Orphan Llc	Uporaba aerosoliziranega levofloksacina za zdravljenje cistične fibroze
MX2011007675A (es)	2011-07-19	2012-07-11	Cell Therapy And Technology S A De C V	Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es)	2012-03-28	2017-03-31	Cell Therapy And Tech S A De C V	Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es)	2012-08-23	2018-06-04	Grupo Medifarma S A De C V Star	Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
WO2016195020A1 (fr)	2015-06-02	2016-12-08	杏林製薬株式会社	Médicament aqueux
US10617684B2 (en)	2015-06-02	2020-04-14	Kyorin Pharmaceutical Co., Ltd.	Aqueous drug
US10406149B2 (en)	2015-06-02	2019-09-10	Kyorin Pharmaceutical Co., Ltd.	Aqueous liquid formulation
MX387370B (es) *	2017-02-13	2025-03-18	Elanco Animal Health Gmbh	Composición líquida que contiene pradofloxacina.
MX366086B (es)	2017-08-15	2019-06-27	Cell Therapy And Tech S A De C V	Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US523505A (en) *		1894-07-24		Island
DE3517709A1 (de) *	1985-01-05	1986-07-10	Bayer Ag	Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) *	1987-01-30	1988-08-04	Dainippon Pharmaceut Co Ltd	ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) *	1988-04-15	1989-10-26	Bayer Ag	I.m. injektionsformen von gyrase-inhibitoren
CA2072366C (fr) *	1989-12-29	2002-08-20	Laman A. Al-Razzak	Complexes d'acide carboxylique d'une quinolone-ion d'un metal-acide
US5084276A (en) *	1990-01-05	1992-01-28	Abbott Laboratories	Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
EP0443381B2 (fr) *	1990-02-14	1997-10-22	Takeda Chemical Industries, Ltd.	Composition effervescente, sa production et son utilisation
FR2665635A1 (fr) *	1990-08-10	1992-02-14	Merck Sharp & Dohme	Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) *	1990-08-29	1992-01-21	Schering Corporation	Pharmaceutical composition of florfenicol
US5235054A (en) *	1992-07-15	1993-08-10	Pfizer Inc.	3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) *	1993-09-17	1995-03-28	Tanabe Seiyaku Co Ltd	動物用注射剤

1996
- 1996-11-13 DE DE69618987T patent/DE69618987T2/de not_active Expired - Lifetime
- 1996-11-13 PL PL96328001A patent/PL186795B1/pl unknown
- 1996-11-13 CZ CZ19981930A patent/CZ293747B6/cs not_active IP Right Cessation
- 1996-11-13 NZ NZ501160A patent/NZ501160A/en not_active IP Right Cessation
- 1996-11-13 CA CA002239352A patent/CA2239352C/fr not_active Expired - Lifetime
- 1996-11-13 SK SK807-98A patent/SK284412B6/sk not_active IP Right Cessation
- 1996-11-13 NZ NZ320545A patent/NZ320545A/xx not_active IP Right Cessation
- 1996-11-13 RU RU98111831A patent/RU2141827C1/ru active
- 1996-11-13 ES ES96935251T patent/ES2167609T3/es not_active Expired - Lifetime
- 1996-11-13 BR BR9612230A patent/BR9612230A/pt active IP Right Grant
- 1996-11-13 AU AU73289/96A patent/AU709474B2/en not_active Expired
- 1996-11-13 EP EP96935251A patent/EP0868183B1/fr not_active Expired - Lifetime
- 1996-11-13 AT AT96935251T patent/ATE212551T1/de active
- 1996-11-13 KR KR10-1998-0704719A patent/KR100402570B1/ko not_active Expired - Lifetime
- 1996-11-13 PT PT96935251T patent/PT868183E/pt unknown
- 1996-11-13 DK DK96935251T patent/DK0868183T3/da active
- 1996-11-13 JP JP52344797A patent/JP3416145B2/ja not_active Expired - Lifetime
- 1996-11-13 HU HU9903726A patent/HU227918B1/hu unknown
- 1996-11-13 CN CN96199249A patent/CN1104899C/zh not_active Expired - Lifetime
- 1996-11-13 UA UA98063226A patent/UA56151C2/uk unknown
- 1996-11-13 IL IL12445496A patent/IL124454A/xx not_active IP Right Cessation
- 1996-11-13 SI SI9630422T patent/SI0868183T1/xx unknown
- 1996-11-13 WO PCT/IB1996/001217 patent/WO1997023217A1/fr not_active Ceased
- 1996-11-15 TW TW085114021A patent/TW449475B/zh not_active IP Right Cessation
- 1996-12-10 PE PE1996000892A patent/PE25798A1/es not_active Application Discontinuation
- 1996-12-17 EG EG113496A patent/EG24071A/xx active
- 1996-12-18 TN TNTNSN96163A patent/TNSN96163A1/fr unknown
- 1996-12-18 MA MA24427A patent/MA24035A1/fr unknown
- 1996-12-18 DZ DZ960191A patent/DZ2146A1/fr active
- 1996-12-19 GT GT199600098A patent/GT199600098A/es unknown
- 1996-12-19 AP APAP/P/1996/000898A patent/AP706A/en active
- 1996-12-19 AR ARP960105774A patent/AR005147A1/es active IP Right Grant
- 1996-12-19 US US08/769,809 patent/US5811130A/en not_active Expired - Lifetime
- 1996-12-19 HR HR960607A patent/HRP960607B1/xx not_active IP Right Cessation
- 1996-12-20 RS YU69096A patent/RS49523B/sr unknown
- 1996-12-20 CO CO96066993A patent/CO4480098A1/es unknown
- 1996-12-20 MY MYPI96005411A patent/MY117109A/en unknown
- 1996-12-20 ZA ZA9610780A patent/ZA9610780B/xx unknown
1998
- 1998-05-25 IS IS4755A patent/IS2010B/is unknown
- 1998-06-12 OA OA9800082A patent/OA10697A/en unknown
- 1998-06-15 BG BG102542A patent/BG63933B1/bg unknown
- 1998-06-19 MX MX9805026A patent/MX9805026A/es unknown
- 1998-06-19 NO NO19982842A patent/NO315734B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69618987T2 (de)	2002-11-21
HRP960607A2 (en)	1998-06-30
TNSN96163A1 (fr)	2005-03-15
SK80798A3 (en)	1999-09-10
RU2141827C1 (ru)	1999-11-27
NO982842D0 (no)	1998-06-19
EP0868183A1 (fr)	1998-10-07
NO315734B1 (no)	2003-10-20
HRP960607B1 (en)	2002-06-30
PE25798A1 (es)	1998-05-21
BG102542A (en)	1999-06-30
WO1997023217A1 (fr)	1997-07-03
BR9612230A (pt)	1999-07-13
ES2167609T3 (es)	2002-05-16
CN1104899C (zh)	2003-04-09
JPH11501331A (ja)	1999-02-02
AU7328996A (en)	1997-07-17
CA2239352A1 (fr)	1997-07-03
CA2239352C (fr)	2002-06-04
ATE212551T1 (de)	2002-02-15
SK284412B6 (sk)	2005-03-04
PT868183E (pt)	2002-06-28
NZ501160A (en)	2001-10-26
HUP9903726A2 (hu)	2000-04-28
AR005147A1 (es)	1999-04-14
KR100402570B1 (ko)	2003-12-18
US5811130A (en)	1998-09-22
YU69096A (sh)	1999-06-15
NO982842L (no)	1998-06-19
GT199600098A (es)	1998-06-12
EP0868183B1 (fr)	2002-01-30
HU227918B1 (en)	2012-06-28
BG63933B1 (bg)	2003-07-31
MA24035A1 (fr)	1997-07-01
EG24071A (en)	2008-05-11
ZA9610780B (en)	1998-06-22
DE69618987D1 (de)	2002-03-14
TW449475B (en)	2001-08-11
MY117109A (en)	2004-05-31
AP706A (en)	1998-12-04
AU709474B2 (en)	1999-08-26
UA56151C2 (uk)	2003-05-15
IS2010B (is)	2005-05-13
CZ193098A3 (cs)	1999-05-12
KR19990076617A (ko)	1999-10-15
IL124454A (en)	2003-10-31
PL186795B1 (pl)	2004-02-27
HUP9903726A3 (en)	2001-01-29
RS49523B (sr)	2006-10-27
NZ320545A (en)	2000-03-27
CN1205636A (zh)	1999-01-20
JP3416145B2 (ja)	2003-06-16
CZ293747B6 (cs)	2004-07-14
MX9805026A (es)	1998-09-30
AP9600898A0 (en)	1997-01-31
SI0868183T1 (en)	2002-04-30
IS4755A (is)	1998-05-25
DK0868183T3 (da)	2002-03-25
CO4480098A1 (es)	1997-07-09
IL124454A0 (en)	1998-12-06
PL328001A1 (en)	1999-01-04
DZ2146A1 (fr)	2002-10-23

Publication	Publication Date	Title
OA10697A (en)	2001-05-04	Injectable quinolone formulations.
US4081528A (en)	1978-03-28	Tetracycline compositions
CS199527B2 (en)	1980-07-31	Manufacturing process of the steady antibiotic agent
AU2006271870B2 (en)	2011-11-24	Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2002529415A (ja)	2002-09-10	製薬学的モキシフロキサシン調製物
CA2391539A1 (fr)	2001-05-25	Utilisation de polymeres de poli(diallylamine)
CA2011063C (fr)	1999-07-06	Compose pharmaceutique de nicardipine pour administration parenterale
CA2421410A1 (fr)	2002-03-28	Compositions a base de fer
US4772460A (en)	1988-09-20	Method of reducing the swelling or pain associated with antibiotics compositions
JP3648531B2 (ja)	2005-05-18	ファモチジン注射液
WO2002102743A3 (fr)	2003-03-13	Aminoalkylesters d'acide diphenylalcoxy-acetique n et alpha-substitues deuterises et medicaments contenant lesdits composes
CA1135188A (fr)	1982-11-09	Compositions a base d'oxytetracycline
PL364801A1 (en)	2004-12-13	Taste masked compositions
JP2002508330A (ja)	2002-03-19	ダルホプリスチンおよびキヌプリスチンに基づく医薬組成物ならびに調製
US5674872A (en)	1997-10-07	Treatment of ovarian cancer
US6110905A (en)	2000-08-29	Long-acting oxytetracycline composition
JP3330977B2 (ja)	2002-10-07	ダピプラゾール含有経口投与用固体医薬組成物
AU699436B2 (en)	1998-12-03	Treatment of non-small cell lung carcinoma
EP0337733A2 (fr)	1989-10-18	Dose unitaire pour le traitement par voie intramusculaire d'infections par chlamydia trachomatis
ATE288269T1 (de)	2005-02-15	Arzneizusammensetzungen und herstellungsverfahren von ergotalkaloidhaltigen arzneizusammensetzungen mit verzögerter wirkstoffabgabe und verbesserter bioverfügbarkeit
CA2163772A1 (fr)	1994-12-08	Solution d'injection intramusculaire et sous-cutanee pour les animaux
HU176305B (hu)	1981-01-28	Eljárás stabil tetraciklin-készítmények előállítására
HK1012267B (en)	2003-07-18	Use of topotecan in the treatment of non-small cell lung carcinoma